Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. news covered the company's shift from AI-driven oncology drug discovery into digital asset treasury and AI compute infrastructure activities. Recurring updates included financial results, Nasdaq listing compliance, a reverse stock split, private placements, governance changes, and the Aethir (ATH) token strategy tied to a Strategic Compute Reserve.
The company's oncology-related updates centered on its artificial intelligence and machine-learning platform, tumor sample biorepository, CLIA laboratory capabilities, and collaborations for drug repurposing and cancer therapy response prediction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Predictive Oncology Inc. (NASDAQ: POAI) announced a reverse stock split of its common stock at a ratio of 1-for-20, effective April 24, 2023, at 12:01 a.m. This decision aims to comply with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. Following the split, the number of outstanding shares will decrease from approximately 79.6 million to about 3.98 million. Stockholders’ interests will remain proportionate, although fractional shares will be rounded up. The reverse split was authorized by stockholders on April 19, 2023, during a special meeting. The company also noted that there will be proportional adjustments to equity awards, convertible preferred stock, and warrants.